Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 20/20 | 0.65 |
| ▸ | SLC2A3 | P11169 | 19/20 | 0.65 |
| ▸ | SLC2A4 | P14672 | 17/20 | 0.65 |
| ▸ | SLC2A2 | P11168 | 9/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18320785 | 0.93 | SLC2A1 (0.65) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320574 | 0.93 | SLC2A1 (0.72) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320547 | 0.92 | SLC2A1 (0.74) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320998 | 0.91 | SLC2A1 (0.80) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320796 | 0.90 | SLC2A1 (0.68) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL16832622 | 0.89 | SLC2A1 (0.78) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18321238 | 0.88 | SLC2A1 (0.73) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320858 | 0.88 | SLC2A1 (0.73) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320734 | 0.88 | SLC2A1 (0.73) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL18320989 | 0.88 | SLC2A1 (0.69) | SLC2A1SLC2A3SLC2A4SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016202898-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | claimed |
| WO-2016202898-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |